Exploration of the Therapeutic Effect of Zoledronic Acid Combined with Salmon Calcitonin in Patients with Primary Osteoporosis
Objective To study the effect of combined treatment with zoledronic acid and salmon calcitonin on pa-tients with primary osteoporosis.Methods A total of 90 patients with primary osteoporosis treated at Jingjiang People's Hospital of Yangzhou University from January 2020 to December 2022 were unrandomly selected as the study subjects.They were divided into the control group and the observation group by difference treatment,with 45 cases each.The treatment plans were single salmon calcitonin and salmon calcitonin combined with zoledronic acid re-spectively,with a treatment period of 3 months for both groups.The effective rate of treatment,bone metabolism and bone density indicators,and incidence of adverse reactions between groups were calculated.Results The total efficacy was higher in observation group(93.33%)than 77.78%in the control group,the difference was statistically significant(χ2=4.405,P<0.05).After treatment,the bone density index and 25(OH)D in the observation group were higher than those in the control group,β-CTX was lower than that in the control group,the differences were statistically signifi-cant(all P<0.05);The number of adverse reactions in the observation group was greater than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Choosing the combination of zoledronic acid and salmon calcitonin in the treatment of primary osteoporosis patients can improve clinical efficacy,improve bone me-tabolism and bone density,and have good drug safety.
NETL
NSTL
万方数据
